MUC1, PD-L1, CD70, and CD44v6 have been identified as promising targets for CAR-T cells in the treatment of HNSCC and have been confirmed in preclinical studies [380–382] (Fig. 3). Here, CD274 is linked to head and neck squamous cell carcinoma.